Vivos Therapeutics Inc. (NASDAQ: VVOS) completed a private placement raising $2.25 million from V-Co Investors 3 LLC, an affiliate of New Seneca Partners Inc., the company announced. The transaction closed on March 31, 2026.

The funding includes the conversion of a previously announced $1.4 million bridge note, with gross proceeds adjusted for a $140,000 original issue discount. Vivos sold common stock, a pre-funded warrant, and two common stock purchase warrants exercisable at $1.09 per share over two and five years. The purchase price was set at $1.34 per share to comply with Nasdaq listing requirements.

Since 2024, affiliates of New Seneca Partners have invested a total of $13.4 million in Vivos. The medical device company focuses on treating breathing-related sleep disorders and obstructive sleep apnea.

Vivos plans to use the net proceeds for general working capital purposes. The company has been transitioning from a dentist-focused business model to a medical affiliation approach, including its 2025 acquisition of operating assets from The Sleep Center of Nevada.

Michael Skaff, Managing Director of New Seneca Partners, stated the investment reflects support for Vivos' strategic shift toward affiliations with sleep and cardiology practices. The company aims to achieve breakeven operating cash flow by the end of 2026.

Vivos disclosed additional details about the private placement in a Form 8-K filing with the Securities and Exchange Commission on April 3, 2026. The company's devices have received FDA clearance for treating obstructive sleep apnea in adults and children.